Physician profile
Christopher D Brabazon
NPI 1942260435
$4,357.67
in general payments reported to CMS, 2019-2025
29 companies · $1,171 in 2025
The $1,171 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $157 · 2023: $1,701 · 2024: $1,329 · 2025: $1,171.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,200.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $703.61 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $567.93 | 2022-2025 | Qulipta, Ubrelvy, Vraylar |
| Glaxosmithkline, LLC. | $527.46 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $414.72 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $385.22 | 2023-2025 | Mounjaro, Zepbound, Emgality |
| Pfizer INC. | $377.51 | 2022-2025 | |
| Exact Sciences Corporation | $200.99 | 2023-2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $140.41 | 2023-2024 | Xarelto |
| Abbott Laboratories | $118.47 | 2023-2025 | Freestyle Libre 3, Freestyle Libre |
| Otsuka America Pharmaceutical, INC. | $108.89 | 2023-2024 | Rexulti |
| Dexcom, INC. | $104.86 | 2023-2025 | Dexcom G6 Transmitter |
| Phathom Pharmaceuticals, INC. | $87.85 | 2024-2025 | Voquezna |
| Sumitomo Pharma America, INC. | $82.47 | 2023-2024 | Gemtesa |
| Astellas Pharma US INC | $80.29 | 2023-2025 | Veozah, Myrbetriq |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $74.04 | 2025 | Caplyta |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.75 | 2023-2024 | Synjardy, Jardiance |
| Merck Sharp & Dohme LLC | $44.09 | 2024-2025 | Capvaxive, Gardasil 9, Gardasil |
| Axsome Therapeutics, INC. | $43.13 | 2024 | Auvelity |
| Bayer Healthcare Pharmaceuticals INC. | $36.35 | 2024-2025 | |
| Sonex Health, INC. | $31.52 | 2025 | Sx-One Microknife |
| International Rehabilitative Sciences, INC | $30.02 | 2023 | Rs 4i Plus Sequential Stimulator |
| Kyowa Kirin, INC. | $28.88 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.93 | 2025 | Xifaxan |
| Mannkind Corporation | $20.13 | 2025 | |
| Lundbeck LLC | $17.46 | 2024 | Rexulti |
| Vanda Pharmaceuticals INC. | $17.15 | 2025 | Fanapt |
| Xeris Pharmaceuticals, INC. | $16.64 | 2025 | Gvoke Hypopen |
| Amgen INC. | $13.14 | 2022 | |
| Sanofi-Aventis U.S. LLC | $12.76 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Brabazon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.